


AMENDMENT TO CLAIMS:

Claims 1-26 (canceled)

27. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a separated and purified, or synthetic procyanidin oligomer.
28. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
29. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
30. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
31. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is B-2 procyanidin.
32. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is B-5 procyanidin.
33. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

34. (previously added) The pharmaceutical composition of claim 27, adapted for administration by injection.

{W:\DOCS\NIPC\1010\100us3\00001397.DOC}

35. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
36. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
37. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
38. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is B-2 procyanidin.
39. (currently amended) The pharmaceutical composition of claim 34, wherein procyanidin oligomer is B-5 procyanidin.
40. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

41. (previously added) The pharmaceutical composition of claim 27, adapted for nasal administration.
42. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
43. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
44. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.

{W:\DOCS\N\JPC\1010\100us3\00001397.DOC}

45. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is B-2 procyanidin.
46. (currently amended) The pharmaceutical composition of claim 41, wherein procyanidin oligomer is B-5 procyanidin.
47. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

48. (previously added) The pharmaceutical composition of claim 27, adapted for rectal administration.
49. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
50. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
51. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
52. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is B-2 procyanidin.
53. (currently amended) The pharmaceutical composition of claim 48 wherein procyanidin oligomer is B-5 procyanidin.

{WADOCS\NJPC\1010\0100us3\00001397.DOC}

54. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

55. (previously added) The pharmaceutical composition of claim 27, adapted for vaginal administration.
56. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
57. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
58. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
59. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is B-2 procyanidin.
60. (currently amended) The pharmaceutical composition of claim 55, wherein procyanidin oligomer is B-5 procyanidin.

(W:\DOCS\NJPC\1010\0100us3\00001397.DOC)

61. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

62. (currently amended) The pharmaceutical composition of claim 27, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
63. (previously added) The pharmaceutical composition of claim 34, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
64. (previously added) The pharmaceutical composition of claim 41, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
65. (previously added) The pharmaceutical composition of claim 48, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
66. (previously added) The pharmaceutical composition of claim 55, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
67. (new) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is synthetic.
68. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
69. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
70. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.

{W:\DOCS\NJPC\1010\0100us3\00001397.DOC}

71. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is B-2 procyanidin.
72. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is B-5 procyanidin.
73. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer has the following formula:



wherein n is 2 to 5.

74. (new) The pharmaceutical composition of claim 67, adapted for administration by injection.
75. (new) The pharmaceutical composition of claim 67, adapted for nasal administration.
76. (new) The pharmaceutical composition of claim 67, adapted for rectal administration.
77. (new) The pharmaceutical composition of claim 67, adapted for vaginal administration.
78. (new) The pharmaceutical composition of claim 67, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.

{WADOCS\N\PC\1010\0100US3\00001397.DOC}